Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Chronic Graft-versus-host Disease (cGVHD)
85%
Acute Myeloid Leukemia
43%
Hematopoietic Stem Cell Transplantation
41%
Hematopoietic Cell Transplantation
32%
Overall Survival
30%
Autologous Stem Cell Transplantation (auto-SCT)
27%
Graft-versus-host Disease (GvHD)
27%
95% Confidence Interval
25%
Non-relapse Mortality
23%
Progression-free Survival
22%
Transplantation
18%
Reduced-intensity Conditioning
18%
Quality of Life
17%
Diffuse Large B-cell Lymphoma (DLBCL)
17%
Hematological Malignancies
16%
Phase II Trial
15%
Myelodysplastic Syndrome
14%
Allogeneic Transplantation
14%
Hazard Ratio
14%
Cyclophosphamide
13%
Steroid-refractory
13%
High Risk
13%
Phase I Study
12%
Busulfan
12%
Umbilical Cord Blood Transplantation
12%
FMS-like Tyrosine Kinase 3 (FLT3)
11%
Marrow Transplant
11%
Isocitrate Dehydrogenase 1 (IDH1)
11%
Lymphoma
11%
Maintenance Therapy
11%
Non-Hodgkin Lymphoma
10%
First Complete Remission
10%
Corticosteroids
10%
Minimal Residual Disease
10%
Bone Marrow Transplantation
10%
Tyrosine Kinase Inhibitor
9%
Reduced Intensity
9%
Hematopoietic Stem Cell Transplant
9%
Rituximab
9%
Chimeric Antigen Receptor T Cells (CAR-T)
8%
Mount Sinai
8%
Gastrointestinal Tract
8%
Survivors
8%
Matched Unrelated Donor
8%
Double Umbilical Cord Blood
8%
Clinical Trials
8%
International Consortium
8%
Graft-versus-host Disease Prophylaxis
7%
Myeloablative
7%
Immunology and Microbiology
Hematopoietic Cell
68%
Graft-Versus-Host Disease
64%
Cell Transplantation
61%
Acute Graft Versus Host Disease
60%
Overall Survival
28%
Hematopoietic Stem Cell Transplantation
24%
Myeloid
20%
Steroid
20%
Chronic Graft Versus Host Disease
19%
Allogeneic Hematopoietic Stem Cell Transplantation
18%
Allograft
17%
Progression Free Survival
16%
Umbilical Cord Blood
15%
Allogeneic Stem Cell Transplantation
12%
Cyclophosphamide
10%
B Cell
9%
Autologous Stem Cell Transplantation
8%
Cord Blood Stem Cell Transplantation
8%
T Cell
8%
Bone Marrow Transplantation
7%
Regulatory T Cell
7%
Drug Megadose
7%
Allele
7%
Infection
7%
Infectious Disease
7%
Vedolizumab
6%
Tacrolimus
6%
Natural Killer Cell
6%
Human Leukocyte Antigen
5%
Rituximab
5%
Immune Reconstitution
5%
Autologous Hematopoietic Stem Cell Transplantation
5%
Central Nervous System
5%
Medicine and Dentistry
Hematopoietic Cell
47%
Cell Transplantation
42%
Acute Myeloid Leukemia
37%
Hematopoietic Stem Cell Transplantation
31%
Autologous Stem Cell Transplantation
23%
Overall Survival
22%
Progression Free Survival
18%
Graft Versus Host Reaction
18%
Quality of Life
17%
Diseases
17%
Diffuse Large B-Cell Lymphoma
16%
Cyclophosphamide
15%
Reduced Intensity Conditioning
14%
Allogeneic Hematopoietic Stem Cell Transplantation
13%
Busulfan
12%
Acute Graft Versus Host Disease
12%
Allograft
11%
Non-Hodgkin Lymphoma
11%
Myelodysplastic Syndrome
11%
Chronic Graft Versus Host Disease
11%
Hematologic Malignancy
10%
Hazard Ratio
10%
Allogeneic Stem Cell Transplantation
7%
Minimal Residual Disease
7%
Cumulative Incidence
7%
Rituximab
7%
Tyrosine-Kinase Inhibitor
7%
Cytarabine
6%
High Dose Chemotherapy
6%
Thiotepa
6%
Cord Blood
6%
Malignant Neoplasm
6%
Induction Chemotherapy
6%
Chemotherapy
6%
Clinical Trial
5%
Drug Megadose
5%
Posttraumatic Stress Disorder
5%
Kidney Transplantation
5%
Central Nervous System
5%
Maintenance Therapy
5%
Distress Syndrome
5%
Symptomatic Treatment
5%